What OASIS-1 Actually Changes in Clinical Practice

By
Published Updated Last reviewed
GLP-1 medication and metabolic health image for What OASIS-1 Actually Changes in Clinical Practice

At a glance

| Parameter | Detail | |---|---| | Trial | OASIS-1 (NCT05035095) | | N | 667 adults with BMI ≥30 (or ≥27 with comorbidity), without diabetes | | Intervention | Oral semaglutide 50 mg once daily | | Comparator | Matched placebo | | Duration | 68 weeks (16-week dose escalation + 52-week maintenance) | | Primary endpoint | Percent change in body weight from baseline | | Key result | −15.1% vs −2.4% (estimated treatment difference −12.7 percentage points, p<0.0001) | | Publication | The Lancet, 2023 (PubMed 37579925) |

Why This Trial Exists

Before OASIS-1, oral semaglutide was approved only at doses up to 14 mg for type 2 diabetes under the brand name Rybelsus. At that dose, weight loss hovered around 4 to 5%, a modest effect that never positioned the pill as an obesity drug. Injectable semaglutide 2.4 mg (Wegovy) had already shown 15 to 17% weight reduction in the STEP program, but many patients refused or delayed treatment because of needle aversion. The clinical gap was clear: could an oral formulation, dosed higher than existing approvals, match injectable results?

Novo Nordisk designed the OASIS program to answer that question. OASIS-1 enrolled adults with obesity (or overweight with at least one weight-related comorbidity) but explicitly excluded those with type 2 diabetes. The primary publication reported results from 81 sites across 14 countries.

Methodology Worth Noting

Dose Escalation Was Aggressive

Participants started at 3 mg daily for 4 weeks, escalated to 7 mg, then 14 mg, then 25 mg, and finally 50 mg. Each step lasted 4 weeks, meaning the full escalation consumed 16 of the trial's 68 weeks. This matters because it compresses the maintenance-dose exposure to 52 weeks, shorter than the 56 to 60 weeks some injectable trials provided. Any comparison to STEP-1's 68-week results with semaglutide 2.4 mg must account for this difference.

Fasting Requirement Stayed Strict

Oral semaglutide uses the SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) absorption enhancer, which demands the tablet be taken on an empty stomach with no more than 120 mL of water, followed by a 30-minute fast. This protocol already applied to the 14 mg diabetes dose and did not change at 50 mg. Real-world adherence to this fasting window correlates directly with bioavailability; patients who eat within 15 minutes absorb substantially less drug.

Estimand Structure

OASIS-1 used two estimands. The "treatment policy" estimand captured all randomized participants regardless of treatment discontinuation or rescue medication, reflecting intention-to-treat principles. The "trial product" estimand included only data while on treatment without rescue intervention. The headline 15.1% weight loss figure comes from the treatment policy analysis, which is the more conservative and clinically applicable number. Under the trial product estimand, weight loss reached 17.4%.

Key Results Beyond the Headline

Weight Loss Trajectory

Weight was still declining at week 68. The curve had not plateaued. This is clinically significant because it suggests that longer treatment duration (beyond the trial's window) could produce additional loss. In contrast, the injectable semaglutide STEP-1 curve showed clear flattening by week 60.

Categorical Responders

| Threshold | Oral semaglutide 50 mg | Placebo | |---|---|---| | ≥5% weight loss | 85% | 26% | | ≥10% weight loss | 69% | 12% | | ≥15% weight loss | 54% | 6% | | ≥20% weight loss | 34% | 3% |

More than one-third of patients on the active drug lost at least 20% of their body weight. This responder rate sits in the same range as tirzepatide 15 mg in SURMOUNT-1, a dual GIP/GLP-1 agonist that was, until these data, the oral-free comparator everyone referenced.

GI Tolerability and Discontinuation

Gastrointestinal adverse events occurred in 80% of the oral semaglutide group versus 46% on placebo. Nausea was the most common (53.7% vs 16.8%). However, the discontinuation rate due to adverse events was 12%, broadly comparable to injectable semaglutide trials where rates ran from 7% to 10%. Most GI symptoms clustered in the dose-escalation phase and resolved with continued use.

What Actually Changes in Practice

1. The Injection Barrier Collapses for a Defined Subgroup

Surveys consistently show 20 to 30% of patients with obesity decline injectable therapy when first offered. OASIS-1 gives clinicians a pharmacologically equivalent oral option for these patients. This is not theoretical. The American Association of Clinical Endocrinology obesity guidelines already stratify therapy by efficacy tier. An oral formulation that hits the "high efficacy" bracket (≥15% weight loss) reclassifies the pill from a convenience option to a primary-tier treatment.

2. Prescribing Patterns for Primary Care Shift

GLP-1 injectables for obesity have been largely prescribed by endocrinologists and obesity medicine specialists. Primary care physicians, who manage the vast majority of patients with overweight and obesity, have been slower to adopt injectable regimens. Oral formulations sit within the familiar prescribing model (daily pill, written Rx, standard pharmacy fill). The practical result: a broader prescriber base. This mirrors what happened when oral GLP-1 agonists entered the diabetes space, where primary care adoption rates rose faster than for injectables.

3. Formulary and Access Questions Are Unresolved

As of mid-2026, oral semaglutide 50 mg does not have a separate FDA-approved obesity indication under a distinct brand. The existing Rybelsus label covers only up to 14 mg for type 2 diabetes. Novo Nordisk has filed for expanded indications, but until approval and payer coverage align, the 50 mg dose remains off-label for weight management in patients without diabetes. This creates a gap: the evidence supports it, but insurance coverage does not yet reliably follow.

4. Head-to-Head Context Is Still Missing

OASIS-1 was placebo-controlled. No randomized trial has directly compared oral semaglutide 50 mg to injectable semaglutide 2.4 mg or to tirzepatide at any dose. Cross-trial comparisons are tempting (15.1% vs 14.9% for injectable semaglutide in STEP-1), but differences in population, baseline BMI, and duration make such comparisons unreliable for treatment decisions. Clinicians should not tell patients the pill is "just as good" based on separate trials with different populations.

5. Patients Who Differ from the Trial Population

OASIS-1 excluded individuals with type 2 diabetes, prior bariatric surgery, use of other weight-loss medications, and BMI <27. The mean age was approximately 48 years, the mean BMI was 37.5, and roughly 73% of participants were female. Applying these results to patients over 65, those with BMI above 50, or those on concurrent metabolic medications requires caution. The OASIS-2 trial (which included participants with type 2 diabetes) provides complementary data for that subgroup but showed lower absolute weight loss, as expected.

Limitations the Authors Acknowledged

The trial was not powered or designed for cardiovascular or mortality endpoints. Bone density and lean mass were not measured, an increasingly relevant omission given concerns about muscle loss with GLP-1 agonists. The 68-week duration, while standard for regulatory purposes, does not address durability. Data from the STEP-1 extension showed rapid weight regain after semaglutide discontinuation, and there is no reason to assume oral dosing behaves differently on that front.

The trial population was predominantly White (71%) and drawn from sites in Europe, North America, and a limited number of centers in Asia. Generalizability to underrepresented populations remains an open question.

The Bottom Line for Clinicians

OASIS-1 proves that an oral GLP-1 agonist at a dose four times higher than the current diabetes approval can match injectable-tier weight loss. That is a genuine clinical advance. The practical implications depend on three pending variables: regulatory approval of the 50 mg dose for obesity, insurance coverage decisions, and whether real-world adherence to the fasting protocol holds outside trial conditions. Until all three align, the published trial data support informed, off-label discussions between clinician and patient, not routine first-line oral prescribing.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once a day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2023;402(10403):705-719. PubMed
  2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed
  3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(4):327-340. PubMed
  4. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2023. PubMed
  5. Aroda VR, Aberle J, Engberg S, et al. Oral semaglutide 50 mg in type 2 diabetes and obesity (OASIS 2). The Lancet. 2024;403(10422):107-119. PubMed
  6. Rybelsus (semaglutide) prescribing information. U.S. Food and Drug Administration. FDA Label